Form 4: IN8BIO Director Epperly Amends Warrant Terms, Reducing Exercise Price

Corinne Epperly, a director at IN8BIO, INC., amended the terms of outstanding warrants, reducing the exercise price from $1.50 to $0.45 per share.

Summary

• On April 27, 2025, Corinne Epperly, a director at IN8BIO, INC., amended the terms of her Series B warrants.
• The amendment involved the deemed cancellation of the old warrant with an exercise price of $1.50 and the grant of a replacement warrant with a reduced exercise price of $0.45 per share.
• Epperly beneficially owns 81,967 Series B warrants.
• These warrants are fully vested and exercisable.
• The warrants expire on December 13, 2028.
• The warrants relate to 81,967 shares of common stock.
• The warrants were originally granted on December 13, 2023, as part of units purchased for $1.22 each, which included one share of common stock, one Series A warrant, and one Series B warrant.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The warrant amendment could be seen as slightly positive as it may incentivize warrant exercise, but it's not a major event.

Positives

• The reduction in the exercise price of the warrants could make them more attractive to the holder.

Industry Context

Warrant amendments are sometimes used to incentivize warrant holders to exercise their options, which can provide the company with additional capital.

Stakeholder Impact

• Shareholders may see this as a slightly positive development if the warrant amendment leads to increased capital for the company.

Key Dates

Keywords

IN8BIO, Epperly, warrant amendment, Series B warrants, exercise price, director, beneficial ownership